Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Stock Quote Today & Recent News Spero Therapeutics Inc SPRO

Healthcare Biotechnology
Spero Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on identifying and developing novel treatments for rare diseases and diseases caused by multi-drug resistant (MDR) bacterial infections with unmet need. Its product candidate SPR720 is an investigational, chemically stable phosphate ester prodrug that is converted in vivo to SPR719 for the treatment... see more
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >

Current News (NDAQ:SPRO)

Spero Therapeutics Announces Third Quarter 2025 Operating Results and Provides a Business Update

GlobeNewswire 11 minutes ago

Spero Therapeutics to Report Third Quarter 2025 Financial Results and Provide Business Update on November 13, 2025

GlobeNewswire 9 days ago

PIVOT-PO Phase 3 Data Show Tebipenem HBr's Potential as the First Oral Carbapenem Antibiotic for Patients with Complicated Urinary Tract Infections (cUTIs)

GlobeNewswire October 21, 2025

Spero Therapeutics Announces Presentations on Tebipenem Hbr at IDWeek

GlobeNewswire October 14, 2025

Spero Therapeutics Announces Second Quarter 2025 Operating Results and Provides a Business Update

GlobeNewswire August 12, 2025

Spero Therapeutics to Report Second Quarter 2025 Financial Results and Provide Business Update on Tuesday, August 12, 2025

GlobeNewswire August 5, 2025

Spero Therapeutics and GSK Announce PIVOT-PO Phase 3 Study for Tebipenem HBr Stopped Early for Efficacy Following Review by Independent Data Monitoring Committee

GlobeNewswire May 28, 2025

Spero Therapeutics Announces First Quarter 2025 Operating Results and Provides a Business Update

GlobeNewswire May 13, 2025

Spero Therapeutics to Report First Quarter 2025 Financial Results and Provide Business Update on Tuesday, May 13, 2025

GlobeNewswire May 5, 2025
View More News ››

Opinion & Analysis (NDAQ:SPRO)

No current opinion is available.
View More Opinion ››

Bullboard Posts (NDAQ:SPRO)

Buy buddy buy because it's taking off this morning.

Otherwise you guys out there will be missing out on this stock today and big profits too
coolfooldumbguy - May 28, 2025

Small Cap Stocks with 3-Year Revenue Growth Rates +100%?

17:04 - Spero Therapeutics, Inc. | NASDAQ: SPRO Small Cap Stocks with 3-Year Revenue Growth Rates +100%? | TDR SMall Cap Sunday...
Betteryear2 - October 30, 2024

Spero Therapeutics, Inc. (NASDAQ:SPRO) &#8211; A Promising P

http://beyondspx.com/2024/08/02/spero-therapeutics-inc-nasdaqspro-a-promising-pipeline-targeting-rare-diseases-and-resistant-infections/
MikeTester - August 3, 2024

SPRO ....can'y win em all

Sorry
Iseneschal - September 22, 2022

SPRO ..... watching for Volume increase and Price Action

Might run again....currently at ~$2.40
Iseneschal - September 22, 2022

SPRO .... In PB mode

Stops save portfolios....just sayin ; ) Next support...... ~ $2.11  JMHO
Iseneschal - September 22, 2022
View more Bullboard ››

Sky Gold Corp.

Sky Gold Corp.

Sky Gold Corp. is a Canada-based junior mineral exploration company. The Company is engaged in acquiring and advancing ...
View More »